Pharmacogenomic Optimization of Anesthetic Dosing: Toward Precision Medicine in Perioperative Care

Abstract

Pharmacogenomic optimization of anesthetic dosing is an emerging paradigm in perioperative medicine, aiming to individualize drug selection and dosing based on genetic variability. Recent advances have illuminated the profound impact of single nucleotide polymorphisms and other genetic variations on anesthetic drug metabolism, efficacy, and risk of adverse events. This review synthesizes current evidence, elucidating mechanistic underpinnings, risk stratification, clinical implementation, and guideline-based recommendations, with a focus on practical applications for anesthesiologists and perioperative care teams. Integration of pharmacogenomics into anesthetic management promises improved patient safety, efficacy, and outcomes, marking a pivotal shift toward precision medicine in anesthesia.

Introduction

The inter-individual variability in response to anesthetic agents poses significant challenges in perioperative medicine. Pharmacogenomics—the study of how genetic makeup influences drug response—offers a pathway toward precision anesthetic care. By leveraging genetic information, clinicians can optimize anesthetic drug choice and dosing, minimizing adverse effects and maximizing therapeutic efficacy. The application of pharmacogenomics in anesthesia is supported by growing evidence, with implications for commonly used agents such as opioids, volatile anesthetics, muscle relaxants, and local anesthetics. This review explores the scientific rationale, clinical relevance, and future directions for pharmacogenomic-guided anesthetic dosing.

Epidemiology / Disease Burden

Annually, millions of patients worldwide undergo surgeries requiring anesthesia, with an estimated 310 million major surgical procedures performed globally each year. Adverse drug reactions (ADRs) related to anesthetic agents contribute to significant perioperative morbidity and mortality, with studies reporting incidences of severe ADRs ranging from 0.1% to 0.7%. Inter-patient variability in anesthetic response, owing largely to genetic factors, is implicated in both suboptimal anesthesia and heightened risk of complications. The economic and patient safety burden of ADRs underscores the urgency of adopting precision strategies such as pharmacogenomics in anesthesia.

Pathophysiology

Genetic polymorphisms in drug-metabolizing enzymes, transporters, and receptors critically influence the pharmacokinetics and pharmacodynamics of anesthetic drugs. Cytochrome P450 enzymes (e.g., CYP2D6, CYP3A4, CYP2C9), pseudocholinesterase (BCHE), and UDP-glucuronosyltransferases (UGTs) are key determinants of anesthetic metabolism. Variants in these genes can result in rapid, intermediate, or poor metabolizer phenotypes, altering drug clearance and leading to under- or over-exposure. Likewise, genetic variability in opioid receptors (OPRM1), GABA receptors, and ryanodine receptors (RYR1) modulate drug efficacy and the risk of adverse reactions such as opioid-induced respiratory depression or malignant hyperthermia. Understanding these mechanisms enables tailored anesthetic regimens based on a patient’s genetic profile.

Risk Factors

Risk factors for suboptimal anesthetic response or adverse events include inherited genetic variants, family history of anesthesia complications, prior unexplained reactions to anesthesia, and underlying comorbidities that affect drug metabolism. For example, patients carrying CYP2D6 gene duplications may metabolize codeine to morphine more rapidly, increasing the risk of toxicity, whereas CYP2D6 poor metabolizers may experience inadequate analgesia. Similarly, BCHE deficiency is a well-established risk factor for prolonged neuromuscular blockade with succinylcholine. Ethnic background also plays a role, as the prevalence of certain pharmacogenomic variants differs among populations.

Clinical Features

Clinically, pharmacogenetic variability may manifest as unexpected sensitivity or resistance to anesthetic agents, prolonged recovery time, opioid toxicity, inadequate anesthesia or analgesia, postoperative delirium, or severe reactions such as malignant hyperthermia. Early recognition of these features is crucial for prompt management and prevention of complications. For instance, patients with OPRM1 A118G polymorphism may require higher opioid doses for adequate analgesia, while those with RYR1 mutations are at risk for life-threatening hypermetabolic crises with volatile anesthetics.

Diagnosis

Pharmacogenomic testing is increasingly accessible, allowing preoperative identification of at-risk individuals. Diagnostic approaches include targeted genotyping for known variants (e.g., CYP2D6, CYP3A4, BCHE, RYR1) and comprehensive pharmacogenomic panels. Integration of genetic results into the electronic medical record and clinical decision support systems enables real-time, evidence-based anesthetic planning. Additionally, thorough preoperative assessment should incorporate family history, previous anesthesia records, and existing comorbidities to guide testing and interpretation.

Treatment & Management

Effective management involves tailoring anesthetic drugs and dosing to each patient’s pharmacogenomic profile. For example, opioid selection and titration can be informed by CYP2D6 and OPRM1 status, while alternatives to succinylcholine are preferred in BCHE-deficient patients. Perioperative monitoring may be intensified for individuals at risk of prolonged sedation or malignant hyperthermia. Multidisciplinary collaboration among anesthesiologists, pharmacists, geneticists, and surgeons is essential for implementing personalized anesthesia protocols and ensuring patient safety.

Recent Advances / Emerging Therapies

Recent advances include the development of rapid point-of-care pharmacogenomic assays, integration of pharmacogenetic data into electronic health records, and the establishment of clinical decision support tools. Novel research has identified additional gene-drug interactions, such as the influence of SCN9A on local anesthetic sensitivity and UGT2B7 on opioid metabolism. Emerging therapies aim to harness next-generation sequencing and machine learning to predict complex drug response phenotypes and optimize perioperative care. Ongoing clinical trials are evaluating the impact of pharmacogenomic-guided anesthetic protocols on patient outcomes and healthcare costs.

Guideline Recommendations

Professional societies, including the Clinical Pharmacogenetics Implementation Consortium (CPIC), recommend consideration of pharmacogenomic testing for selected gene-drug pairs with strong evidence of clinical impact. For instance, CPIC guidelines provide dosing recommendations for CYP2D6-metabolized opioids and suggest alternative agents for patients with known susceptibilities. The American Society of Anesthesiologists endorses the integration of genetic risk assessment into perioperative planning, particularly in cases with a history of adverse reactions or high-risk genotypes. Implementation requires institutional commitment to education, infrastructure, and multidisciplinary collaboration.

Conclusion

Pharmacogenomic optimization of anesthetic dosing represents a transformative advance in perioperative medicine, bridging the gap between genetic science and clinical practice. By individualizing drug selection and dosing based on genetic makeup, clinicians can reduce adverse events, enhance efficacy, and improve patient outcomes. As pharmacogenomic knowledge expands and implementation barriers diminish, precision anesthesia will become an integral component of safe and effective perioperative care. Ongoing research, education, and guideline development will be pivotal in translating pharmacogenomics from bench to bedside for the benefit of patients worldwide.